Thursday, 25 August 2011

New rules for Chinese contract manufacturers

China's State Food and Drug Administration (SFDA) is clamping down on its drug contract manufacturing companies. The SFDA aims to prevent the export of counterfeit products.

CABB has completed its acquisition of KemFine


Wednesday, 24 August 2011

Contract manufacturing to double in next 10 years

Business information provider Visiongain predicts that global contract manufacturing revenues will double from 2011 to 2021. The company says revenues will reach $64.07bn in 2016 - with a CAGR of 8.7% between 2010 and 2016 - driven by manufacturing of finished dosage forms.
Pharma Times

Monday, 22 August 2011

Aptuit will sell its clinical trials supplies business to Catalent for $410m

Philadelphia Business Journal

BI plant to exit contract manufacturing

Boehringer Ingelheim's Ben Venue laboratories facility in Ohio is to cease contract manufacturing activities and focus on generics operations. Contract manufacturing work will be transitioned to other Boehringer plants over the next few years.

Dottikon ES will end short hours working at its plants at the end of September 2011 after seeing more new projects


Monday, 15 August 2011

Congress to pass plant inspection law

The US Congress is expected to pass new legislation that will enable the FDA to inspect overseas generic drug manufacturing facilities every two years. Generic drug manufacturers will pay fees totalling $299m/year to fund the inspections in return for speedier approval of products.
New York Times

Jubilant Organosys has signed a $100m manufacturing deal with an undisclosed global firm

The Hindu

Fine chemicals revenues rise at Ampac

Revenues at Ampac Fine Chemicals rose 55% to $30.8m in its Q3 2011 compared to 2010. The company attributed this to increases in revenues from core products in its key therapeutic areas including a 139% rise in revenues from anti-viral products.
Seeking Alpha

Onyx acquired by Ipca Laboratories

Onyx Scientific has been acquired by Ipca Laboratories for £4.6m. The UK-based business will be operated as part of Ipca's Covenance custom manufacturing business unit.
North East Business

Ampac Fine Chemicals will manufacture the API for Chimerix's smallpox drug, CMX001, at its Rancho Cordova, CA, facility

Pharmaceutical Business Review

Tuesday, 9 August 2011

Neuland Laboratories reported revenues rising 14% to $23.2m for its Q1 2012

Neuland Laboratories

AMRI Q2 revenues rise

AMRI reported that Q2 2011 revenues for its development/small scale contract manufacturing rose 18% to $9.1m and for its large scale contract manufacturing rose 21% to $25.5m over 2010.
Albany Business Review

Roche Colorado acquired

ICIG is to acquire Roche Colorado and its Boulder, CO, manufacturing facility for an undisclosed fee. ICIG will operate the business as part of its Corden Pharma unit and rebrand the facility as Corden Pharma Colorado. The facility will continue to supply Roche with a number of APIs.
In-pharma Technologist

Joint inspection programme reports

The EMA, the FDA and Australia's Therapeutic Goods Administration have concluded their joint inspection pilot programme. During the two pilots the agencies exchanged more than 250 documents relating to 54 different medicines and organised 13 collaborative inspections of clinical trials. As a result, the agencies will continue with their collaboration on inspections and build on the lessons learned during the pilot phases.
Wall Street Journal

SynCo Bio Partners has produced the first product batches from its expanded aseptic filling facility

Manufacturing Chemist

Monday, 8 August 2011

DSM seeks CMO partner in Asia

DSM is seeking a partner in Asia for its pharmaceutical products custom manufacturing unit. The company is looking to serve new clients in Asia and smaller customers to reduce its reliance on its current large pharma customer base.
Outsourcing Pharma

Cambrex's Q2 sales rose 17.6% to $67.5m primarily due to higher custom manufacturing sales and generic API volumes


Wacker's Biosolutions business generated sales of €39.0m in Q2 2011 up €0.7m from 2010


Tuesday, 2 August 2011

DSM pharma sales slow

DSM reported that sales for its pharma-facing business unit fell to €178m in Q2 2011 from €195m in the same period in 2010 and H1 sales fell to €341m from €381m. The company said that its pharma sales and results improved compared to Q1, but it is conscious that overall performance of the cluster remains below acceptable levels. DSM attributed the lower Q2 sales to the weaker US dollar and lower volumes at DSM Pharmaceutical Products.